REVERDIL study: validity of salbutamol in determining COPD reversibility prior to formoterol treatment

M. Mathieu, L. G. Vincent, B. Isabelle (Bordeaux, Rueil-Malmaison, France)

Source: Annual Congress 2003 - Pharmacological treatment strategies in COPD
Session: Pharmacological treatment strategies in COPD
Session type: Thematic Poster Session
Number: 432
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Mathieu, L. G. Vincent, B. Isabelle (Bordeaux, Rueil-Malmaison, France). REVERDIL study: validity of salbutamol in determining COPD reversibility prior to formoterol treatment. Eur Respir J 2003; 22: Suppl. 45, 432

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A comparison of nebulized levalbuterol, albuterol, and combined albuterol and ipratropium in patients with stable COPD: preliminary observations
Source: Eur Respir J 2002; 20: Suppl. 38, 246s
Year: 2002

Short-acting bronchodilator reversibility does not predict the response to long-term treatment by indacaterol 150 µg in COPD: REVERBREZ study
Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation
Year: 2013


Effect of a single dose of formoterol and tiotropium in exercise tolerance in COPD patients: preliminary data
Source: Eur Respir J 2003; 22: Suppl. 45, 405s
Year: 2003

Comparative evaluation of formoterol budesonide combination MDI and salbutamol MDI for reversibility testing in patients with obstructive airways disease
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010


Spirometric outcomes of COPD patients with tiotropium compared with salmeterol according to previous maintenance long-acting beta-agonist use
Source: Eur Respir J 2004; 24: Suppl. 48, 289s
Year: 2004

24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol
Source: Annual Congress 2008 - New treatments for asthma
Year: 2008

24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008

A pilot study comparing tiotropium to salmeterol plus fluticasone in moderate COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

COPD: Comparison of bronchodilator responsiveness with glycopyrronium and salbutamol
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019


Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol
Source: Eur Respir J 2001; 17: 368-373
Year: 2001



Nebulized formoterol improves airway function in COPD subjects receiving maintenance tiotropium
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008

Comparative effects of formoterol monotherapy versus formoterol plus tiotropium on dynamic hyperinflation and exercise tolerance in COPD
Source: Annual Congress 2009 - Influence of interventions and comorbidity on exercise performance
Year: 2009



The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 212s
Year: 2006

Efficacy of nebulized arformoterol, a long-acting β2-adrenergic bronchodilator, in patients with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 215s
Year: 2006

Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016


Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 426s
Year: 2001

Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide - a cost-effectiveness analysis
Source: Eur Respir J 2001; 18: Suppl. 33, 517s
Year: 2001

Acute asthma treatment: comparison of formoterol and salbutamol given in cumulative doses in children
Source: Eur Respir J 2001; 18: Suppl. 33, 122s
Year: 2001

Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients
Source: Annual Congress 2010 - COPD: management
Year: 2010


Addition of formoterol Turbuhaler® to budesonide Turbuhaler® increases the time to first severe exacerbation in long-term treatment of mild asthma: results from OPTIMA
Source: Eur Respir J 2001; 18: Suppl. 33, 517s
Year: 2001